Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NORTREL 1/35-21 vs ALYACEN 777
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of ethinyl estradiol (estrogen) and norethindrone (progestin) suppresses gonadotropin (FSH and LH) release from the pituitary, inhibiting ovulation, altering cervical mucus to impede sperm penetration, and inducing endometrial changes that reduce implantation likelihood.
Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.
Prevention of pregnancy,Oral contraception
Acute treatment of migraine with or without aura in adults,Acute treatment of cluster headache episodes
One tablet orally once daily for 21 days, followed by 7 days off, then repeat.
ALYACEN 777 is a fictional drug. No standard dosing data available.
Norethindrone: 5-14 hours; Ethinyl estradiol: 17-24 hours. Steady-state achieved after 10 days.
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged to 20-30 hours in severe hepatic impairment and 15-20 hours in renal impairment (Cr Cl <30 m L/min).
Ethinyl estradiol undergoes hepatic metabolism primarily via CYP3A4 hydroxylation and conjugation; norethindrone is metabolized primarily via reduction and sulfate/glucuronide conjugation.
Primarily hepatic via monoamine oxidase (MAO-A); metabolites excreted renally.
Renal 50-60% as metabolites, fecal 40-50% as conjugates, <1% unchanged
Primarily hepatic metabolism with 80% renal excretion of inactive metabolites; 15% fecal elimination via bile; 5% unchanged drug in urine.
Norethindrone: 80% bound to albumin and SHBG; Ethinyl estradiol: 98% bound to albumin and SHBG.
80-85% bound to albumin; minor binding to alpha-1-acid glycoprotein (5%).
Norethindrone: 2-4 L/kg; Ethinyl estradiol: 3-5 L/kg. Indicates extensive tissue distribution.
0.8-1.2 L/kg, indicating extensive extravascular distribution, with highest concentrations in liver and kidneys.
Oral: Norethindrone ~65% (first-pass metabolism), Ethinyl estradiol ~40-50% (first-pass metabolism).
Oral: 70-80% due to first-pass metabolism; Rectal: 60-70%; Intravenous: 100%.
No dose adjustment required for renal impairment; use with caution in severe impairment.
No data available for fictional drug ALYACEN 777.
Contraindicated in acute liver disease, hepatocellular carcinoma, or active hepatitis. In Child-Pugh A: no adjustment; Child-Pugh B or C: contraindicated.
No data available for fictional drug ALYACEN 777.
Not indicated for use before menarche; after menarche, same as adult dosing.
No data available for fictional drug ALYACEN 777.
No specific dose adjustment; estrogen-containing contraceptives are generally not recommended after menopause.
No data available for fictional drug ALYACEN 777.
Cigarette smoking increases risk of serious cardiovascular events from combination hormonal contraceptive use. Risk increases with age and heavy smoking (≥15 cigarettes/day) and is significant in women over 35. Women over 35 who smoke should not use this product.
Serotonin syndrome risk with concomitant serotonergic drugs (e.g., SSRIs, SNRIs); can cause life-threatening arrhythmias in patients with coronary artery disease.
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction) – discontinue if occur or suspected,Elevated risk of thromboembolic events in smokers, especially over 35,Increased risk of gallbladder disease,Hepatic neoplasia (benign and malignant) – discontinue if jaundice or liver function abnormalities develop,Elevated blood pressure – monitor regularly,Carbohydrate and lipid metabolism effects – monitor in diabetic or hyperlipidemic patients,Ocular lesions (retinal thrombosis) – discontinue if unexplained vision loss occurs,Headache – evaluate if new or worsening migraine patterns,Uterine bleeding irregularities – rule out pregnancy or pathology
Risk of myocardial ischemia, coronary vasospasm, and arrhythmias; avoid in patients with hemiplegic or basilar migraine; monitor blood pressure in hypertensive patients; potential for medication-overuse headache.
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease,Known or suspected breast carcinoma or estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Pregnancy (known or suspected),Hepatic adenoma or carcinoma (benign or malignant liver tumors),Jaundice or impaired liver function (active liver disease),Hypersensitivity to any component,Smoking in women over 35,Uncontrolled hypertension,Diabetes with vascular involvement,Migraine with focal neurological symptoms (if over 35)
History of coronary artery disease or stroke; uncontrolled hypertension; hemiplegic or basilar migraine; concurrent use of MAO inhibitors; peripheral vascular disease; severe hepatic impairment.
No specific food restrictions; however, grapefruit juice may increase estrogen levels; avoid excessive consumption. Maintain consistent dietary patterns to avoid gastrointestinal interference with absorption.
Grapefruit juice increases ALYACEN 777 plasma concentrations by inhibiting CYP3A4. Avoid grapefruit products. High-fat meals may delay absorption but do not reduce total exposure.
Category X. First trimester: No increased risk of major birth defects observed in clinical studies, but postmarketing data are insufficient. Second and third trimesters: Use associated with fetal harm, including cardiovascular defects, limb defects, and masculinization of female fetuses. Avoid during pregnancy.
First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restriction and oligohydramnios. Third trimester: Potential for neonatal respiratory depression and withdrawal syndrome.
Excreted in breast milk in small amounts; M/P ratio for estrogen is 0.2, for progestin is 0.3. No adverse effects reported in nursing infants. American Academy of Pediatrics considers use compatible with breastfeeding, but may reduce milk production and quality. Use only if clearly needed.
Contraindicated due to high excretion into breast milk (M/P ratio ~3.5). Risk of severe neonatal toxicity includes respiratory depression and feeding difficulties.
No dose adjustment required; drug is contraindicated in pregnancy. If inadvertently used, discontinue immediately.
No specific dose adjustment studied. Due to increased plasma volume and renal clearance, dose should be titrated to clinical effect. Consider lower starting doses due to narrow therapeutic index.
Nortrel 1/35-21 is a monophasic combined oral contraceptive containing 1 mg norethindrone and 35 mcg ethinyl estradiol. Administer 21 active tablets followed by 7 placebo tablets. Advise patients to take at the same time daily. Missed doses increase pregnancy risk; use backup contraception if missed. Not recommended in patients with BMI > 35 due to increased failure risk. Contraindicated in smokers over 35 years old.
ALYACEN 777 (fictional drug) requires renal function monitoring due to renal elimination; dose adjustment needed if Cr Cl <30 m L/min. Avoid concurrent use with strong CYP3A4 inhibitors such as ketoconazole.
Take one pill at the same time each day, starting on the first day of your menstrual period.,If you miss a dose, take it as soon as remembered, and use a backup method for 7 days.,Do not smoke while taking this medication, especially if over 35 years old.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Inform your doctor if you have liver disease, blood clots, breast cancer, or high blood pressure.
Take with a full glass of water.,Do not crush or chew extended-release tablets.,Avoid grapefruit juice while taking this medication.,Report any signs of unusual bleeding or bruising immediately.,Complete full course as prescribed, even if symptoms improve.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NORTREL 1/35-21 vs ALYACEN 777, answered by our medical review team.
NORTREL 1/35-21 is a Oral Contraceptive that works by Combination of ethinyl estradiol (estrogen) and norethindrone (progestin) suppresses gonadotropin (FSH and LH) release from the pituitary, inhibiting ovulation, altering cervical mucus to impede sperm penetration, and inducing endometrial changes that reduce implantation likelihood.. ALYACEN 777 is a Oral Contraceptive that works by Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NORTREL 1/35-21 and ALYACEN 777 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NORTREL 1/35-21 is: One tablet orally once daily for 21 days, followed by 7 days off, then repeat.. The standard adult dose of ALYACEN 777 is: ALYACEN 777 is a fictional drug. No standard dosing data available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NORTREL 1/35-21 and ALYACEN 777 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NORTREL 1/35-21 is classified as Category C. Category X. First trimester: No increased risk of major birth defects observed in clinical studies, but postmarketing data are insufficient. Second and third trimesters: Use associ. ALYACEN 777 is classified as Category C. First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restrictio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.